Status:
COMPLETED
Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study
Lead Sponsor:
McGill University
Conditions:
Human Papillomavirus Infection
Eligibility:
All Genders
18-45 years
Phase:
PHASE4
Brief Summary
Human papillomavirus (HPV) is a member of the Papillomaviridae family of DNA viruses that is capable of infecting humans. HPV infection can cause cancers of the cervix, vulva, vagina, and anus in wome...
Detailed Description
Two prophylactic vaccines (Gardasil by Merck, and Cervarix by GlaxoSmithKline) have been proven in randomized controlled trials (RCT) to be highly effective in preventing infection against the target ...
Eligibility Criteria
Inclusion
- Couple must have been in a new relationship that started no more than six months prior to study entry
- Both partners plan on remaining in Montreal for at least 1 year
- Plan on having continued sexual contact with partner
- Be willing to comply with study procedures
Exclusion
- Volunteers must not have been vaccinated against HPV-Gardasil-9 (both partners)
- Any history of cervical, penile, oral or anal cancers
- Being pregnant or plan on immediately becoming pregnant
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2022
Estimated Enrollment :
372 Patients enrolled
Trial Details
Trial ID
NCT01824537
Start Date
January 1 2014
End Date
November 18 2022
Last Update
March 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
McGill University - Division of Cancer Epidemiology
Montreal, Quebec, Canada, H4A 3T2